At the news
? BULLISHIMPACT 8/10 DEFA14A filed Apr 13, 2026 at 17:27 ET
Centessa Pharmaceuticals is soliciting shareholder approval for its acquisition by Eli Lilly, expected to close in Q3 2026. The filing includes employee FAQs addressing benefits, equity payouts, and transition plans, signaling progress toward deal closure. Shareholders will vote on the proposed scheme of arrangement.
- Eli Lilly is acquiring Centessa Pharmaceuticals, with transaction expected to close in Q3 2026.
- Shareholder vote is required to approve the acquisition via a court-sanctioned scheme of arrangement under UK law.
- Employees will transition to Eli Lilly's benefit plans post-closing; 2026 bonuses will be pro-rated between Centessa and Lilly plans.
- No material opposition or competing bids have been disclosed; regulatory and court approvals are pending.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access